

# Lipid Based Nanoparticles For Treatment Of Cancer

*Tejaswini Bhausahab Jouk, Manisha Savle, Dr Gajanan Sanap*

*LBYP College of Pharmacy, Pathri, Aurangabad, Maharashtra, India*

## Abstract

Investigators were continuously creating new nanotechnologies to address unmet conditions throughout the administration of remedial drugs & imaging agents for cancer treatment & diagnostics, meetly. LNPs( Lipid nanoparticles) are licit particulates(approx. 100 nm in size) gathered from colorful lipid as well as other biochemical composites which overall functionality to resolve natural walls( bio barriers), allowing LNPs to widely collect nearly outside of complaint- target cells again for responsive rectifiers. utmost pharmaceutically important composites were undoable throughout water results, were chemical & physiologically unstable, or have venom. Among the most implicit medicine carrier for bioactive organic composites is LBNPs( Lipid grounded nanoparticles) technologies. Its present use in chemotherapy have converted treatment for cancer by adding the antitumor effect of a number of chemotherapeutics. Because they may be created using naturally being sources, LBNPs have great temporal and thermal stability, maximum cargo eventuality, simplicity of medications, cheap manufacturing costs, & big manufacturing affair. likewise, combining chemotherapeutic medicines with LNPs reduces active remedial lozenge and venom, lowers treatment resistance, & raises medicine attention in tumour cells while reducing attention in normal towel. LBNPs were extensively studied in cancer treatment, both in vitro and in vivo, with encouraging issues in certain clinical trials. This study provides an overview of the numerous types of LBNPs which have been created in rearmost times and their operations and benefactions in different types of cancers.


**Key Words:** *Lipid based Nanopartcles, Tumour, Liposomes ,Solid lipid nanoparticles Clinical trials.*

## Introduction:

Tumour is a order of illness that are explained as irregular cell development with capability to spread toward other cells or areas of the body. It's among the biggest killers, of over 100 distinct forms of cancer(1). Inside the uninhabited nation, conditions likeH. pylori, hbv, hep C, hpv infection, Epstein – Barr contagions, and HIV beget 15 of malice( 2). Those variables serve, at least in part, through altering a cell's genes. numerous inheritable differences are frequently necessary before cancer thresholds(3). Cancers are caused by inherited inheritable abnormalities in 5 – 10 of cases( 4).Medical tests, in addition to colorful suggestions and pointers, can assist in determining malice. Additionally, it would typically be investigated further using individual imaging and confirmed by vivisection.(5). During 2015, around90.5 million individualities were diagnosed with cancer(6). In 2019, there were almost 18 million new cases reported annually. ( 7). It was criticized for nearly8.8 million deaths each and every time( 8). Lung cancer, prostate cancer, colorectal cancer, and stomach cancer are the most current kinds of cancer in men( 9). bone cancer, colorectal cancer, lung cancer, and cervical cancer are the most current kinds of cancer in women( 10). Skin cancers other than carcinoma would regard for around 40percent of new cases of cancer per time if total new cancer cases had been included( 11, 12). Acute lymphoblastic & brain cancer feel to be the most frequent in youths, other than in African, whereinnon-Hodgkin cancer is more frequent( 13).

" Fat" seems to be another term for" lipid." The lipids feel to be a material which is unfit to dissolve undoable in h2o but having capability to dissolve in alcoholic,( C2H5) 2O, & chl3( 14). Lipids were essential factors of mortal

cells. Lipids, along with Cx( H<sub>2</sub>O) y & proteins, were its primary factors of factory and beast cells. Triglycerides and cholesterol are both lipids. Lipids are fleetly achieved and retained within system. It serves as an energy reference and is an important element of cell composition. Lipids include adipose acids, neutral fats, waxes, and steroids( like cortisone). emulsion lipids include lipoproteins, glycolipids, and phospholipids( lipids perplexed with another type of chemical patch). Lipids are occasionally defined as aquaphobic or amphipathic small motes; the amphiphilic specific of certain lipids enables us to make conformations in an waterless terrain like vesicle, large uniflagellar liposomes, or membrane. The two kinds of biochemical subunits, or "structure blocks," that make up biological lipid are isoprene and ketoacyl groups.. Structure of SLN, Liposomes and Lipid conflation are shown in [Figure 1]




**Figure 1. The overall arrangement of solid lipid nanoparticles, which have benefits over liposomes and lipid emulsions, is represented schematically. Adopted from [60].**

Because of their biocompatibility as transporters, lipids have gotten a lot of attention since the morning of the pharmacological period. They've little oral immersion due to their largely hydrophobic nature( 15). As a consequence, the desire to extend the range of operations for similar carriers was wrong, and they are not employed in propulsion systems till 1900, while they were boxed into colloidal delivery systems( 16, 17, 18, 19). Lipid nanoparticles( LNPs) were seen to be more salutary than polymeric nanoparticles in the creation of nanoparticle- grounded delivery systems, and they have been extensively employed for medicine delivery( 20). Because LNPs are made from physiologic and/ or biodegradable lipids, these lipid- grounded carrier systems are also appertained to as " Nano safe " carriers( 21). The veritably well LNP conflation is solid lipid nanoparticles( SLNs), that were created in the early 1990s( 22). Because of the colorful benefits of previous carriers like emulsifiers, liposomes, & polymeric nanoparticles, that delivering system was introduced( 23). The feasibility of the product procedures and levelling- up process, the GRAS( generally recognised as safe) quality of all phrasings, and the lack of polar composites are the characteristics that distinguish SLNs from liposomes( 24).

Recently, tumor nanotechnology has been developed as a possible cancer therapeutic approach for the delivery of antitumor drugs [25]. With diameters ranging from 1 to 1000 nm, nanoparticles improve the specificity of anticancer drugs and their therapeutic bioavailability [26]. Figure 2 displays the many nanoparticles (NPs) and nanotech approaches to cancer treatment that have recently been presented. Semiconductor quantum dots (QDs) hold great potential as a flexible material system for biological applications due to their unique optical properties, wide excitation spectrum, and excessively narrow symmetric intensity distribution. A fascinating new class of fluorescent

components is semiconductor quantum dots (QDs). They are used in applications such as biosensing, biolabeling, and bioimaging. QDs are more effective than regular fluorophores.

They are less photobleached, brighter, and more controllable in terms of fluorescence intensity. A single light source can excite different colored QDs, which have broad absorption and narrow emission spectra. For screening cell receptors, the aforementioned QDs seem to be the best option. It is necessary to modify the surface of QDs using different biological materials in order to produce efficient fluorescence probes [27].



**Figure 2. Nanotechnology based tools utilized in treatment of cancer. Adopted from [61].**

Among the colorful nano phrasings utilised in cancer shown in Figure 2., we emphasize those grounded on lipid phrasings since substantial improvements in medication and indispensable compositions have been realised in recent decades. Chemical changes to lipid nano systems can be used to shirk vulnerable system discovery or to increase drug vacuity. These could also be manufactured in pH-sensitive compositions to increase release of the medicine in an acidic condition, and they can be coupled along antibodies those descry tumour cells & their receptor like( FoA) folic acid( 28). Nano medicines can potentially be utilised in confluence with other treatment approaches to increase patient ,,s response. multitudinous antitumour medicines, including cisplatin, irinotecan( IRI), paclitaxel( PTX), doxorubicin( DOX), oxaliplatin, daunorubicin, cytarabine, and vincristine, have formerly been analysed in nano phrasings, and some were delved in clinical studies and/ or are commercially present for their



clinical application( 29). In fact, first commercially utilised anticancer medicine NanoSystems was Doxil ®, a liposome expression containing DOX. provides an overview of the numerous types of LBNPs( Figure 3) which have been created in rearmost times and their operations and benefactions in different types of cancers.




Figure 3. Lipid based nanoparticles showing A) LIPOSOMES, B) LIPID NANOEMULSIONS C) LIPID NANOPARTICLES, D) SOLID LIPID NANOPARTICLES, E) NANOSTRUCTURED LIPID CARRIERS. Adopted from[62].

### Solid lipid nanoparticles

These are hard sized ranged between 1- 1000nanometer. The size of patches substantially between 150-300nanometer. SLNs have a diameter range of 1e1000 nm and are solid, submicronic colloidal nanocarriers. The flyspeck size is substantially between 150 and 300 nm. similar delivery of medicines styles, like polymeric nanoparticles, give a frame for regulated releases( 30). Their solid matrix of SLNs allows them to circumscribe drug motility & offer better stabilization, allowing them to combine the benefits of polymeric nanoparticles, liposomes, and micronized emulsifiers( 31). also, tests show that SLNs were largely profitable in a variety of aspects( Figure 4), similar as the forestallment of utilising organic detergent while manufacturing, possible scaling( 32), as well as the addition both of lipophilic and hydrophilic drugs in significant amounts( 33). SLNs are created by replacing a solid lipid or indeed a combination of solid lipids for the liquid lipid( oil painting) in the structure of an oil painting in water conflation. One important point of SLNs is that they've been solid at both room as well as temperature of body( 34). similar medicine transport systems are composed of 0.1 – 30( w/ w) solid lipid dispersed in an waterless medium. SLNs are generally composed of solid form lipid similar as advanced chastity of triglycerides, free adipose acids, free adipose alcohols, complex glyceride composites, and indeed wax( generally well- known physiologic lipids)( 35). It's also doable to use more complicated structures( 36).




Figure 4. The Benefits and uses of SLN are depicted schematically. Adopted from [63].

#### Medical applications of SLN:

##### 1. Cancer chemoimmunotherapy:

Tumour chemoimmunotherapy would be a drug which combines all salutary goods of chemotherapeutic with immunotherapeutic. Chemo generally entails use of similar traditional cytotoxic drugs as well as new molecularly targeted treatments. Immunotherapy, on the other hand, is a fairly new kind of cancer treatment

which employs the inpatient's native vulnerable system to fight cancer cells. It includes the Immune checkpoint impediments, consanguineous cell remedy, cancer vaccinations, & cytokine curatives are all being used.


**2. Nanoparticles based on lipids in cancer immunotherapy:**

Due to specific benefits, nanotech has entered a lot of interest in cancer remedy( 37). Nanoparticle, in illustration, similar as Polymeric micelles, lipid- grounded nanoparticles, gold nanoparticles, and inorganic nanoparticles are all exemplifications of nanoparticles, are constantly employed to transport rectifiers including small motes( either hydrophilic or hydrophobic), protein, & heredity accoutrements for chemotherapeutic agents. Those nanomaterials can transport remedial medicines to certain cells via passively fastening ways like the EPR impact or active targeting ways like specific ligand( 38).

Lipid- grounded nanoparticles, in particular, have appealing pharmacological & multifunctional parcels, similar as bio-compatibility, bio-degradability, as well as the eventuality to blackjack both aquaphilic and aquaphobic curatives( 39, 40, 41). likewise, the face characteristics of lipid- grounded nanoparticles may be readily changed by changing the lipid factors or altering the face. Presently some of that are under preclinical trails similar as cold-blooded lipid- grounded nanoparticles, nano discs, & liposomes, some of these are given in **Table 1**.

**Lipid based nanoparticles in clinical trials :**

Type of Composition		Chemotherapy	Immunotherapy	Cancer
Liposomes				
PEGylated	Doxorubicin	Alendronate	liposomes	Breast cancer
Charge-reversal				
cell penetrating	Paclitaxel	PD-L1 antibody		Melanoma peptide-
modified liposomes				
pH-responsive		Indoximod		Breast cancer and
liposomes	Mitoxantrone			renal cancer



**Application in cancer therapy :**

Lipid- Grounded NPs( LBNPs) are a vast and diversified class of nanoparticles that are especially important in BreC remedy(42). But besides their diversity, liposomes are extensively employed because to their great biocompatibility and capability to synopsize a wide range of loadings. LBNPs are now being employed in a number of studies, and a many of them( for illustration, Doxil ® or Abraxane ®) have preliminarily been certified for BreC remedy( 6, 43). This part presents the most recent major improvements in the use of LBNPs in the treatment of the most common kinds of cancer.



### 1. Bowel cancer:

Bowel cancer is a major health concern because of its high death rate (it is the alternate leading cause of death) and the recent increase in its prevalence (44, 45). LBNPs give a possible system for perfecting being treatments, particularly in advanced colorectal cancer where chemotherapy (5-FU alone or in combination with other drugs) or monoclonal antibodies (bevacizumab, trastuzumab, cetuximab) are ineffective. In comparison to a 5-FU thermosensitive gel-intermediated microemulsion (ME), a thermosensitive gel-intermediated 5-FU microemulsion (ME) was suitable to enhance Caco-2 permeability and cell uptake, as well as its accumulation in rectal towel in vivo.

### 2. Stomach cancer:

It's the globe's 5th another veritably frequent malice as well as the major cause of malice mortality (44,45). Only stomach malice that has not spread to the lymph bumps could be managed via surgical junking only. Severe stomach melanoma, should be managed with combination chemotherapy, which have significant adverse impacts. New treatments counting upon nano expression are presently being explored to enhance patient responses. Liposomes were astronomically applied in GC remedy, either alone or in combination with composites including the Arg- Gly- Asp peptides (46), SATB1 siRNA/ CD44 antibodies (47), or in the conformation of DNA complexes (48). Their use enhanced medicine deposit in cancerous cells of any creatures grafted with SGC7901 cells expressing high situations of integrin 51 (46). Liposomes also displayed increased targeting delicacy and were suitable to suppress SATB1 gene expression by about 80 in CD44 GC starting cells (47). likewise, liposomes recognised peritoneally dispersed GC MKN- 45P cells, dwindling their accumulation in the liver. original studies using SLNs in GC (49) revealed that etoposide (VP16) had increased action in SGC- 7901 cell, adding inhibition of growth, causing cell apprehensions in the G2/ M stage (17.13 percent), & driving mitochondria- involved apoptotic. Li et al. (50) created an SLN for use in confluence with in ATRA and sorafenib as well as miR-542-3p. This system bettered the immersion of both anticancer drugs and had a synergistic exertion on MGC- 803 cells.

### 3. Breast tumour:

It's the leading cause of mortality in women (44) and is passing significant shifts as a result of the development of NPs, specially in the treatment of metastatic cancer. Throughout the tolerant MCF- 7/ ADR cancer cell, NEs preloaded wit DOX & bromo tetra trandrine (W198, P- glycoprotein (P- gp) asset) have been examined. That increased cellular immersion and deposit of DOX in cancer cells. DOX, on the other hand, reduced stomach & cardiac damage (51). In discrepancy, DOX- liposome- grounded compositions were estimated in clinical studies. PLD in confluence to lapatinib have been lately utilised in HER2-positive BreC victims (stage Ib) to find the stylish confluence including both curatives at the loftiest respectable lozenge (52). likewise, a phase 3 trials of Myocet in combination with cyclophosphamide (CM) or vinorelbine (MV) in cancer cases BreC has also been established (53). SLNs are another type of LBNP employed in BreC examinations. Yu et al. (54) suggested a system for combining PTX & derivatized DNA delivery with such a pH-sensitive ligand. In vivo, this approach is responsible for reducing tumour volume while also lowering PTX deposit in all farther organs. likewise, Garg et al. (55) created a fucose-methotrexate SLN that accumulated preferentially in tumour towel just 2 h after treatment, as opposed to free methotrexate, that accumulates throughout the order, liver, & spleen.

### 4. Glandular carcinoma:

Presently, the primary LBNPs under delved as implicit treatment styles in prostate cancer include NEs, liposomes, and solid- lipid NPs (SLNs) (PrC). Ahmad et al. (56) lately created an oil painting- in- water NE containing a toxoid remedial agent linked to an omega- 3 adipose acid. That NE is effective to lessen the toxoid IC50 of PPT2 cell types 12-fold, enabling for a larger tumour size drop in tumour- bearing rats than Abraxane™. In PC- 3 cells, analogous antitumor goods were seen when NE was loaded with catechin excerpt (flavanols having anticancer conditioning) (57). Regarding liposomes, 22Rv1 PrC cells were treated with cut- folate- targeted- oleuropein- liposomes.



## 5. Brain Tumors:

Brain tumors include a wide range of tumors that can be primary or metastatic. The primary brain excrescences are known as gliomas. The metastatic bones arise from near malice and also develop within the brain( 58, 59). In this respect, the World Health Organization( WHO recognizes two major types of brain excrescences), gliomas and nongliomas.

## Conclusion and future challenges :

Lipid Grounded Nanoparticles are a varied and comprehensive order of composites that have been utilised to treat colorful conditions, most specially malice. Liposomes are now the most frequently utilised Lipid Grounded Nanoparticles because to its excellent biocompatibility & inflexibility; although, SLNs as well as NLCs have recently gained fashionability. nevertheless, studies are just not concentrated primarily on similar Nanoparticles, and there are several papers fastening on new ways for utilising Lipid Grounded Nanoparticles to heal other kinds of cancer. Some of it has formerly progressed towards the coming stage & began new careers in clinical studies. SLNs and nanostructured lipid carriers have entered a lot of interest in the recent decade as prospective delivery of medicines( nano) systems. One „s main benefit may be the utilisation of biomaterial, environmentally safe constituents and ways of product( Figure 5). It really should be stressed, still, that previous to mass handiwork & distribution of these schemes, rigorous clinical and environmental safety analysis must be done. The establishment of standardised processes for assessing possible troubles of nano- accoutrements consumption, as well as the corresponding nonsupervisory terrain, is considered necessary. As with other nanosized medicine carriers, carcinoma remedy is an important exploration area in which SLNs can be used, which might also represent both large position of backing in the field as well as the felicitousness of nanostructures for similar delivering of cytotoxic medicines, owing to the direct and circular attacking urged by nasty cellular position. nevertheless, there are multitudinous clinical sectors which decide value from using lipid nanoparticles. Regrettably, further exploration, redundant trouble & working capital installations should be handed for SLN/ NLC to be shown therapeutically effective in real- world circumstances. For said time being, the oddity of SLNs which have advanced to medical studies suggests that it would be at least a many times before similar inventions approach the public or transnational medicine request.

## Reference :

1. Underwood J.C., Cross S.S. Elsevier heath science; Amsterdam, Netherlands: 2009. General and Systematic Pathology. [[Google Scholar](#)]
2. Cancer. World Health Organization; 12 September 2018. [[Google Scholar](#)]
3. World Cancer Report 2014. World Health Organization; 2014. Chapter 1.1. [[Google Scholar](#)]
4. Rehder H. Family cancer syndromes. *Hered. Tumors.* 2009;41–86. [[Google Scholar](#)]
5. How Is Cancer Diagnosed? American Cancer Society; 29 January 2013. [[Google Scholar](#)]
6. GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet.* 8 October 2016;388(10053):1545–1602. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
7. Sciacovelli Marco, Schmidt Christina, Maher Eamonn R., Frezza Christian. Metabolic drivers in hereditary cancer syndromes. *Annu. Rev. Cell Biol.* 2020;4:77–97. [[Google Scholar](#)]

8. GBD 2015 Mortality and Causes of Death, Collaborators Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 8 October 2016;388(10053):1459–1544. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
9. World Cancer Report 2014. World Health Organization; 2014. Chapter 1.1. [[Google Scholar](#)]
10. World Cancer Report 2014. World Health Organization; 2014. Chapter 1.1. Archived from the original on 12 July 2017. [[Google Scholar](#)]
11. Dubas L.E., Ingraffea A. Nonmelanoma skin cancer. *Fac. Plastic Surg. Clin. North Am.* February 2013;21(1):43–53. [[PubMed](#)] [[Google Scholar](#)]
12. Cakir B.Ö., Adamson P., Cingi C. Epidemiology and economic burden of nonmelanoma skin cancer. *Fac. Plastic Surg. Clin. North Am.* November 2012;20(4):419–422. [[PubMed](#)] [[Google Scholar](#)]
13. World Cancer Report . Vol. 2014. 2014. World Health Organization. pp. Chapter 1.3. Archived from the original on 12 July 2017. [[Google Scholar](#)]
14. IUPAC . second ed. The "Gold Book"; 1997. Compendium of Chemical Terminology. Online corrected version: (2006–) "lipids". [[Google Scholar](#)]
15. Jingling Tang J.S. Self-emulsifying drug delivery systems: strategy for improving oral delivery of poorly soluble drugs. *Curr. Drug Ther.* 2007;2 [[Google Scholar](#)]
16. Humberstone A.J., Charman W.N. Lipid-based vehicles for the oral delivery of poorly water-soluble drugs. *Adv. Drug Deliv. Rev.* 1997;25 [[Google Scholar](#)]
17. Kuentz M. Lipid-based formulations for oral delivery of lipophilic drugs. *Drug Discov. Today Technol.* 2012;9 [[PubMed](#)] [[Google Scholar](#)]
18. Patel A.R., Velikov K.P. Colloidal delivery systems in foods: a general comparison with oral drug delivery. *Food Sci. Technol.* 2011;44 [[Google Scholar](#)]
19. Pouton C.W., Porter C.J. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. *Adv. Drug Deliv. Rev.* 2008;60 [[PubMed](#)] [[Google Scholar](#)]
20. Müller R.H., Karsten K., Mäder S.G. Solid lipid nanoparticles (SLN) for controlled drug delivery e a review of the state of the art. *Eur. J. Pharm. Biopharm.* 2000;50(1) 66 CHAPTER 3 Lipid-Based Nanoparticles for Drug Delivery Systems. [[PubMed](#)] [[Google Scholar](#)]
21. Pardeike J., Hommoss A., Müller R.H. Vol. 366. 2009. Lipid Nanoparticles (SLN, NLC) in Cosmetic and Pharmaceutical Dermal Products; pp. 170–184. [[PubMed](#)] [[Google Scholar](#)]
22. Gasco M.R. Method for producing solid lipid microspheres having a narrow size distribution. *U.S. Patent No. 5.* 1993;250:236. [[Google Scholar](#)]

23. Müller R.H., Lucks J.S. 1996. Medication Vehicles Made of Solid Lipid Particles (Solid Lipid Nanospheres SLN) [Google Scholar]
24. Doktorovova S., Souto E.B., Silva A.M. Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers e a systematic review of in vitro data. Eur. J. Pharm. Biopharm. 2014;87:1–18. [PubMed] [Google Scholar]
25. Bor G., Mat Azmi I.D., Yagmur A. Nanomedicines for cancer therapy: current status, challenges and future prospects. Ther. Deliv. 2019;10:113–132. [PubMed] [Google Scholar]
26. Miele E., Spinelli G.P., Miele E., Di Fabrizio E., Ferretti E., Tomao S., Gulino A. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int. J. Nanomed. 2012;7:3637–3657. [PMC free article] [PubMed] [Google Scholar]
27. Fatima I., Rahdar A., Sargazi S., Barani M., Hassanisaadi M., Thakur V.K. Quantum dots: synthesis, antibody conjugation, and HER2-receptor targeting for breast cancer therapy. J. Funct. Biomater. 2021;12:75. [PMC free article] [PubMed] [Google Scholar]
28. Rama A.R., Jimenez-Lopez J., Cabeza L., Jimenez-Luna C., Leiva M.C., Perazzoli G., Hernandez R., Zafra I., Ortiz R., Melguizo C., et al. Last advances in nanocarriers-based drug delivery systems for colorectal cancer. Curr. Drug Deliv. 2016;13:830–838. [PubMed] [Google Scholar]
29. Alavi M., Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab. Pers. Ther. 2019;34 [PubMed] [Google Scholar]
30. Muller R.H., Shegokar R., Keck C.M. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr. Drug Discov. Technol. 2011;8(3):207–227. [PubMed] [Google Scholar]
31. Kathe N., Henriksen B., Chauhan H. Vol. 9045. 2014. Physicochemical Characterization Techniques for Solid Lipid Nanoparticles: Principles and Limitations; pp. 1–11. [PubMed] [Google Scholar]
32. Teeranachaidekul V., Muller R.H., Junyaprasert V. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC) e effects of formulation parameters on physicochemical stability. Int. J. Pharm. 2007;340:198–206. [PubMed] [Google Scholar]
33. Jaiswal P., Gidwani B., Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif. Cell Nanomed. Biotechnol. 2014:1–14. [PubMed] [Google Scholar]
34. Lima A.M., Pizzol C.D., Monteiro F.B., Creczynski-Pasa T.B., Andrade G.P., Ribeiro A.O., et al. Hypericin encapsulated in solid lipid nanoparticles: phototoxicity and photodynamic efficiency. J. Photochem. Photobiol., B. 2013;125:146–154. [PubMed] [Google Scholar]
35. Wissing S.A., Kayser O., Mu R.H. Vol. 56. 2004. Solid Lipid Nanoparticles for Parenteral Drug Delivery; pp. 1257–1272. [PubMed] [Google Scholar]
36. Svilenov H., Tzachev C. Solid lipid nanoparticles - a promising drug delivery. Nanomedicine. 2009:187–237. [Google Scholar]
37. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007;2:751–760. [PubMed] [Google Scholar]

38. Zafar A., Alruwaili N.K., Imam S.S., Alharbi K.S., Afzal M., Alotaibi N.H., Yasir M., Elmowafy M., Alshehri S. Novel nanotechnology approaches for diagnosis and therapy of breast, ovarian and cervical cancer in female: a review. *J. Drug Deliv. Sci. Technol.* 2020;61:102198. [[Google Scholar](#)]
39. Ramishetti S., Kedmi R., Goldsmith M., Leonard F., Sprague A.G., Godin B., Gozin M., Cullis P.R., Dykxhoorn D.M., Peer D. Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles. *ACS Nano.* 2015;9:6706–6716. [[PubMed](#)] [[Google Scholar](#)]
40. Khan A., Imam S.S., Aqil M., Ahad A., Sultana Y., Ali A., Khan K. Brain targeting of temozolomide via the intranasal route using lipid-based nanoparticles: brain pharmacokinetic and scintigraphic analyses. *Mol. Pharm.* 2016;13:3773–3782. [[PubMed](#)] [[Google Scholar](#)]
41. Khan A., Aqil M., Imam S.S., Ahad A., Sultana Y., Ali A., Khan K. Temozolomide loaded nano lipid based chitosan hydrogel for nose to brain delivery: characterization, nasal absorption, histopathology and cell line study. *Int. J. Biol. Macromol.* 2018;116:1260–1267. [[PubMed](#)] [[Google Scholar](#)]
42. García-Pinel B., Porrás-Alcalá C., Ortega-Rodríguez A., Sarabia F., Prados J., Melguizo C., López-Romero J.M. Lipid-based nanoparticles: application and recent advances in cancer treatment. *Nanomaterials.* 2019;9(4):638. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
43. Iqbal M.A., S Md, Sahni J.K., Baboota S., Dang S., Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. *J. Drug Target.* 2012;20(10):813–830. [[PubMed](#)] [[Google Scholar](#)]
44. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 2018;68:394–424. [[PubMed](#)] [[Google Scholar](#)]
45. Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M., Znaor A., Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int. J. Cancer.* 2019;144:1941–1953. [[PubMed](#)] [[Google Scholar](#)]
46. Ding J., Feng M., Wang F., Wang H., Guan W. Targeting effect of PEGylated liposomes modified with the Arg-Gly-Asp sequence on gastric cancer. *Oncol. Rep.* 2015;34:1825–1834. [[PubMed](#)] [[Google Scholar](#)]
47. Yang F., Zheng Z., Zheng L., Qin J., Li H., Xue X., Gao J., Fang G. SATB1 siRNA-encapsulated immunoliposomes conjugated with CD44 antibodies target and eliminate gastric cancer-initiating cells. *OncoTargets Ther.* 2018;11:6811–6825. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
48. Wonder E., Simón-Gracia L., Scodeller P., Majzoub R.N., Kotamraju V.R., Ewert K.K., Teesalu T., Safinya C.R. Competition of charge-mediated and specific binding by peptide-tagged cationic liposome–DNA nanoparticles in vitro and in vivo. *Biomaterials.* 2018;166:52–63. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
49. Wang J., Zhu R., Sun X., Zhu Y., Liu H., Wang S.-L. Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through mitochondria-mediated apoptosis pathway. *Int. J. Nanomed.* 2014;9:3987–3998. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]  
Li T., Zhang Y., Meng Y.-P., Bo L.-S., Ke W.-B. miR-542-3p appended sorafenib/all-trans retinoic acid (ATRA)-Loaded lipid nanoparticles to enhance the anticancer efficacy in gastric cancers. *Pharm. Res. (N. Y.)* 2017;34:2710–2719. [[PubMed](#)] [[Google Scholar](#)]



50. Cao X., Luo J., Gong T., Zhang Z.-R., Sun X., Fu Y. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo. *Mol. Pharm.* 2015;12:274–286. [[PubMed](#)] [[Google Scholar](#)]
51. Rocca A., Cecconetto L., Passardi A., Melegari E., Andreis D., Monti M., Maltoni R., Sarti S., Pietri E., Schirone A., et al. Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. *Cancer Chemother. Pharmacol.* 2017;79:863–871. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
52. Lorusso V., Giotta F., Bordonaro R., Maiello E., Del Prete S., Gebbia V., Filipelli G., Pisconti S., Cinieri S., Romito S., et al. Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: a multicenter phase III study. *Int. J. Oncol.* 2014;45:2137–2142. [[PubMed](#)] [[Google Scholar](#)]
53. Yu D., Li W., Zhang Y., Zhang B. Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment. *Biomed. Pharmacother.* 2016;83:1428–1435. [[PubMed](#)] [[Google Scholar](#)]
54. Garg N.K., Singh B., Jain A., Nirbhavane P., Sharma R., Tyagi R.K., Kushwah V., Jain S., Katare O.P. Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics. *Colloids Surf. B Biointerfaces.* 2016;146:114–126. [[PubMed](#)] [[Google Scholar](#)]
55. Ahmad G., El Satta R., Botchkina G., Ojima I., Egan J., Amiji M. Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth. *Cancer Lett.* 2017;406:71–80. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
56. Chen B.-H., Tsai Y.J. Preparation of catechin extracts and nanoemulsions from green tea leaf waste and their inhibition effect on prostate cancer cell PC-3. *Int. J. Nanomed.* 2016;11:1907. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
58. Schiffer D. Springer; VI: 2006. *Brain Tumor Pathology: Current Diagnostic Hotspots and Pitfalls*; p. 272. [[Google Scholar](#)]
59. Laquintana V., Trapani A., Denora N., Wang F., Gallo J.M., Trapani G. New strategies to deliver anticancer drugs to brain tumors. *Expert Opin. Drug Deliv.* 2009;6(10):1017–1032. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
60. Tekade Rakesh K., Maheshwari Rahul, Tekade Muktika, Chougule Mahavir B. Academic Press; 2017. *Solid lipid nanoparticles for targeting and delivery of drugs and genes*; pp. 256–286. [[Google Scholar](#)]
61. Mohanty Chandana. Improvement of cancer therapy by nanotechnology. *Virol. Immunol. J.* 2017;1 [[Google Scholar](#)]
62. InProcess-LSP . AZoNano; 2021, September 30. Lipid-based nanoparticles: manufacturing and inline size characterization. <https://www.azonano.com/article.aspx?ArticleID=5646> Retrieved on May 19, 2022 from. [[Google Scholar](#)]
63. Tekade Rakesh K., Maheshwari Rahul, Tekade Muktika, Chougule Mahavir B. Academic Press; 2017. Chapter 8 - solid lipid nanoparticles for targeting and delivery of drugs and genes, nanotechnology-based approaches for targeting and delivery of drugs and genes; pp. 256–286. [[Google Scholar](#)]